ML327

• CAT Number: I013015
• CAS Number: 1883510-31-3
• Molecular Formula: C₁₉H₁₈N₄O₄
• Molecular Weight: 366.37
• Purity: ≥95%
• Target: c-Myc
• Solubility: DMSO: 32 mg/mL
• Storage: Store at -20°C
• IUPAC Name: N-[3-[(2-oxo-1H-pyridine-3-carbonyl)amino]propyl]-5-phenyl-1,2-oxazole-3-carboxamide
• InChI: InChI=1S/C19H18N4O4/c24-17-14(8-4-9-20-17)18(25)21-10-5-11-22-19(26)15-12-16(27-23-15)13-6-2-1-3-7-13/h1-4,6-9,12H,5,10-11H2,(H,20,24)(H,21,25)(H,22,26)
• InChIKey: NNNDNXLMQAPQQQ-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)C2=CC(=NO2)C(=O)NCCCNC(=O)C3=CC=CNC3=O

ML327 (Cat No.: I013015) is an isoxazole compound with significant therapeutic potential in neuroblastoma. It functions by effectively inhibiting the expression of MYC, a critical oncogene involved in tumor formation. Additionally, ML327 has the ability to restore the expression of E-cadherin, a key protein involved in cell adhesion, with an EC50 of 1.0 μM. This dual action makes ML327 a promising candidate for cancer therapy, particularly in neuroblastoma, as it induces apoptosis in cancer cells, potentially halting their growth and progression. Researchers are actively studying ML327 for its applications in combating this form of cancer.

Reference

[1]. Rellinger EJ, et al. Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma. Oncotarget. 2017 Jul 20;8(53):91040-91051.[2]. An H, et al. Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition.Oncotarget. 2015 Sep 8;6(26):22934-48.